July 22, 2021

Now IRT gets significant update and a portion of new data

[Moscow – 22.07.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.5.0.
IRT represents a Quantitative Systems Pharmacology (QSP) platform of immune system simultaneously being a tool for development of models related to immune system. Its fundamental objective is to facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas.

The new version provides extended data and recalculated parameters:

• Cytokines secretion description by neutrophils, MoDC, NK cells, and Tc1 was added;
• MC model parameters were reestimated;
• ICOS:ICOSL and OX40:OX40L interaction impact was described for T cells models.

Veronika Musatova, Head of IRT development team, sheds the light on the further activity to advance the software, “Now we are enhancing the models of the cells types that have been recently introduced in IRT by the description of their secretion profiles. It is a significant feature to depict the cells roles within the immune response”.

IRT is based on two main components. On the one hand, it is a fully-fledged database that includes a wide variety of features describing the immune system. On the other hand, it comprises Navigator that provides intuitive interface to interact with IRT Database. Thus, a modeler can apply calibrated sub-models exported from IRT as building blocks to simplify the model development process.

IRT is one of InSysBio’s QSP software infrastructure being under constant development and upgrade for both internal and external usage.

To learn the full content of Immune Response Template 3.5.0, please visit irt.insysbio.com.

To get demo access to IRT version 3, please click “sign in” or “user account” on the irt.insysbio.com.

To get more information on any tool or leave your feedback, please feel free to contact us: support@insysbio.com

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 120 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

Share